To lower your risk of cardiovascular disease, focus on lifestyle interventions, as the role of cholesterol and dietary fats is debated among experts.
Our read is that lowering cardiovascular disease risk involves addressing factors beyond just cholesterol levels, with an emphasis on diet and exercise.
Abolishing atherosclerosis could increase lifespan by approximately 3%, and plaque rupture is a significant cause of fatal heart attacks.
However, experts disagree on the primary drivers of heart disease, with some questioning the long-standing focus on LDL cholesterol and saturated fats.
Experts disagree on the primary drivers of cardiovascular disease. Paul Saladino and Peter Attia contend that atherosclerosis is a disease of the tissue, not just plasma lipid levels. Paul Saladino argues that recommendations to consume vegetable oils because they lower LDL are suspect and potentially harmful, given that LDL is not the primary villain in heart disease, and that seed oils are a major driver of chronic disease in humans. He also suggests that the physical dimensions of LDL particles make it improbable for them to directly penetrate the endothelium without causing damage. Peter Attia posits that carbohydrates, not dietary fats, may drive chronic diseases. Rhonda Patrick notes that the combination of high fat and high carbohydrate intake is the worst scenario for adverse health outcomes, including negative changes in lipoprotein profiles. Bryan Johnson warns that frequent short international trips are akin to shift work and increase the risk of diabetes, cardiovascular disease, dementia, and death by 2-2.5 times. Peter Attia also points out that Guinness World Records banned sleep deprivation attempts due to significant health risks including mental health issues, cancer, cardiovascular disease, metabolic syndrome, and suicide.
The verdict could change with a clearer understanding of the exact reasons why arteries retain LDL and veins do not, or if a readily apparent intervention is found to quickly reverse fatty liver disease. Improved prediction of fatal myocardial infarctions would also be a significant development.
Mechanistic and trial evidence converge on a real, replicable effect.
The effect size is large enough to matter clinically, not just statistically.
Mechanistic and trial evidence converge on a real, replicable effect.
The effect size is large enough to matter clinically, not just statistically.
Benefits hold across the populations where it's been tested.
The headline effect shrinks once you account for trial quality.
Animal-model results don't translate to the human protocol being recommended.
The headline effect shrinks once you account for trial quality.
Confounding and publication bias inflate the apparent benefit.
Most of the support comes from short or small studies.